Please assess the completion status of the following clinical trial:

Trial Title: Anticholinergic Burden in Schizophrenia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age of 50 and older~* DSM-IV/SCID diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, or psychotic disorder NOS~* Having been treated with benztopine at a steady daily dose of 3 mg or less for at least three months~* Having been treated with risperidone, quetiapine, olanzapine, or clozapine at a steady dose for at least two weeks.~* Willingness to provide consent for investigator to communicate with their physician of record regarding their participation in the study.~Exclusion Criteria:~* Unstable physical illness or clinically significant neurological disorder~* A history of severe or life-threatening dystonia~* Presence of EPS defined as a total score of 7 or more or a score of 3 or more on any individual item on the SAS at baseline~* Positive urine drug screen for illegal drugs

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).